EBS: Emergent BioSolutions Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
Stocks in this Quantisnow insightHealth Care
Historical context for EBS
Across the 25 sessions after earlier EBS headlines, the stock closed higher 11 times and lower 14 times, with a median move of 2.9% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | EBS | SPY |
|---|---|---|---|
| Sep 3, 2026 | Emergent BioSolutions Completes Repurchase of $75 Million Aggregate Principal Amount of Senior Unsecured Notes | -3.6% | +1.0% |
| Sep 1, 2026 | Emergent BioSolutions Awarded Contract Modification Valued at Approximately $24 Million for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted) | +2.0% | -0.7% |
| Aug 31, 2026 | Emergent BioSolutions Awarded Government of Canada Standing Offer for NARCAN® Nasal Sprayand 1 other headline that session | +3.2% | -0.3% |
| Aug 21, 2026 | Analyst resumed coverage on Emergent BioSolutions | +5.4% | +0.4% |
| Aug 6, 2026 | Emergent BioSolutions Commits to Cross-Sector Collaboration Against Biological Threats in an Evolving Global Security Environmentand 1 other headline that session | -29.6% | -0.2% |
| Jul 23, 2026 | Emergent BioSolutions to Report Second Quarter 2026 Financial Results on August 5, 2026 | -1.1% | -1.2% |
Quantisnow market dataNYSE
EBS
Emergent BioSolutions Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2006
Get push alerts for EBS
Full EBS profile on Quantisnow Follow EBS and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time